
Stefano Tamburin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3142920/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. Expert Review of Neurotherapeutics, 2022, 22, 65-76.	2.8	11
2	Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Critical Reviews in Oncology/Hematology, 2022, 171, 103575.	4.4	18
3	Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol. Brain Sciences, 2022, 12, 573.	2.3	3
4	Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review. Neurology International, 2022, 14, 506-535.	2.8	14
5	Smoking-related cue reactivity in a virtual reality setting: association between craving and EEG measures. Psychopharmacology, 2021, 238, 1363-1371.	3.1	9
6	Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion. Expert Review of Neurotherapeutics, 2021, 21, 235-248.	2.8	7
7	Risk of hospitalization associated with benzodiazepines and zâ€drugs in Italy: a nationwide multicentre study in emergency departments—comment. Internal and Emergency Medicine, 2021, 16, 521-523.	2.0	1
8	Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia. European Journal of Clinical Pharmacology, 2021, 77, 241-249.	1.9	33
9	COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder. Internal and Emergency Medicine, 2021, 16, 1729-1731.	2.0	15
10	Comment on "The association between pain and impulse control behaviours in Parkinson's disease― Parkinsonism and Related Disorders, 2021, 83, 126-127.	2.2	1
11	An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. Expert Review of Neurotherapeutics, 2021, 21, 475-490.	2.8	18
12	Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art. Toxins, 2021, 13, 303.	3.4	5
13	Remote clinical trials: A timely opportunity for a virtual reality approach and its potential application in neurology. British Journal of Clinical Pharmacology, 2021, 87, 3639-3642.	2.4	11
14	Neuromuscular complications of cancer therapy. Current Opinion in Neurology, 2021, 34, 658-668.	3.6	4
15	Olfaction in patients with Parkinson's disease: a new threshold test analysis through turning points trajectories. Journal of Neural Transmission, 2021, 128, 1641-1653.	2.8	1
16	Beyond chronic migraine: a systematic review and expert opinion on the off-label use of botulinum neurotoxin type-A in other primary headache disorders. Expert Review of Neurotherapeutics, 2021, 21, 923-944.	2.8	12
17	Combining Low-Dose Radiation Therapy and Magnetic Resonance Guided Focused Ultrasound to Reduce Amyloid-β Deposition in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1-4.	2.6	Ο
18	Bergamot rehabilitation <scp>AgaiNst</scp> agitation in dementia (<scp>BRAINAID</scp>): Study protocol for a randomized, doubleâ€blind, placeboâ€controlled trial to assess the efficacy of furocoumarinâ€free bergamot loaded in a nanotechnologyâ€based delivery system of the essential oil in the treatment of agitation in elderly affected by severe dementia. Phytotherapy Research, 2021, 35, 5333-5338.	5.8	22

#	Article	IF	CITATIONS
19	Chronic fatigue syndrome: an emerging sequela in COVID-19 survivors?. Journal of NeuroVirology, 2021, 27, 631-637.	2.1	42
20	The Effects of Intensive Neurorehabilitation on Sequence Effect in Parkinson's Disease Patients With and Without Freezing of Gait. Frontiers in Neurology, 2021, 12, 723468.	2.4	2
21	Brain 18F-FDG and 18F-Flumetamol PET Imaging of Fragile X-Associated Tremor Ataxia Syndrome. Clinical Nuclear Medicine, 2021, 46, e344-e346.	1.3	1
22	3T magnetic resonance-guided focused ultrasound thalamotomy in patients with essential tremor: Three-year clinical experience from a single center. Journal of the Neurological Sciences, 2021, 429, 117674.	0.6	0
23	Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug. Journal of Neural Transmission, 2021, 128, 1109-1119.	2.8	6
24	High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde—reply. Internal and Emergency Medicine, 2020, 15, 343-345.	2.0	2
25	Toward a Wearable System for Predicting Freezing of Gait in People Affected by Parkinson's Disease. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 2444-2451.	6.3	49
26	Incentive-driven decision-making networks in de novo and drug-treated Parkinson's disease patients with impulsive-compulsive behaviors: A systematic review of neuroimaging studies. Parkinsonism and Related Disorders, 2020, 78, 165-177.	2.2	6
27	High-Dose Dependence and Cognitive Side Effects to Medical Prescription of Etizolam. Frontiers in Psychiatry, 2020, 11, 601827.	2.6	8
28	Opioids in Post-stroke Pain: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2020, 11, 587050.	3.5	37
29	Detoxification Improves Multidomain Cognitive Dysfunction in High-Dose Benzodiazepine Abusers. Frontiers in Neuroscience, 2020, 14, 747.	2.8	4
30	Exercise training improves vascular function in patients with Alzheimer's disease. European Journal of Applied Physiology, 2020, 120, 2233-2245.	2.5	19
31	Selective atrophy of the brachialis muscle in neuralgic amyotrophy: ultrasound imaging of fascicular nerve damage. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1118-1119.	1.9	6
32	Telemedicine and Virtual Reality for Cognitive Rehabilitation: A Roadmap for the COVID-19 Pandemic. Frontiers in Neurology, 2020, 11, 926.	2.4	102
33	Hedonicity in functional motor disorders: a chemosensory study assessing taste. Journal of Neural Transmission, 2020, 127, 1399-1407.	2.8	1
34	Regulation of microRNAs in Satellite Cell Renewal, Muscle Function, Sarcopenia and the Role of Exercise. International Journal of Molecular Sciences, 2020, 21, 6732.	4.1	30
35	Non-invasive Brain Stimulation for Gambling Disorder: A Systematic Review. Frontiers in Neuroscience, 2020, 14, 729.	2.8	10
36	Non-invasive Brain and Spinal Stimulation for Pain and Related Symptoms in Multiple Sclerosis: A Systematic Review. Frontiers in Neuroscience, 2020, 14, 547069.	2.8	12

#	Article	IF	CITATIONS
37	Vertebral Artery Fenestration Mimicking Acute Dissection. Annals of Neurology, 2020, 88, 235-236.	5.3	3
38	Towards a Redefinition of Cognitive Frailty. Journal of Alzheimer's Disease, 2020, 76, 831-843.	2.6	27
39	Adult Attention-Deficit/Hyperactivity Disorder and Quality of Life in High-Dose Benzodiazepine and Related Z-Drug Users. European Addiction Research, 2020, 26, 274-282.	2.4	8
40	Benzodiazepine Use and HIV-Associated Neurocognitive Impairment: Which Comes First?. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, e26-e27.	2.1	0
41	Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. European Addiction Research, 2020, 26, 263-273.	2.4	7
42	Pharmacological treatment for familial amyloid polyneuropathy. The Cochrane Library, 2020, 4, CD012395.	2.8	8
43	Pharmacological treatment of opioid-induced constipation: moving ahead to new targets. Gut, 2020, 69, 2264-2265.	12.1	0
44	Rehabilitation and Biomarkers of Stroke Recovery: Study Protocol for a Randomized Controlled Trial. Frontiers in Neurology, 2020, 11, 618200.	2.4	3
45	Immune checkpoint inhibitorsâ€induced neuromuscular toxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S74-S85.	3.1	42
46	An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer's Disease: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2019, 71, 813-823.	2.6	23
47	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. Movement Disorders Clinical Practice, 2019, 6, 576-585.	1.5	36
48	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-320969.	1.9	43
49	Nerve size correlates with clinical severity in Charcot–Marie–Tooth disease 1A. Muscle and Nerve, 2019, 60, 744-748.	2.2	14
50	QTc Prolongation in Patients with Dementia and Mild Cognitive Impairment: Neuropsychological and Brain Imaging Correlations. Journal of Alzheimer's Disease, 2019, 72, 1241-1249.	2.6	4
51	Taxane and epothiloneâ€induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S40-S51.	3.1	33
52	Platinumâ€induced peripheral neurotoxicity: From pathogenesis to treatment. Journal of the Peripheral Nervous System, 2019, 24, S26-S39.	3.1	74
53	Chemotherapyâ€induced peripheral neurotoxicity: A multifaceted, still unsolved issue. Journal of the Peripheral Nervous System, 2019, 24, S6-S12.	3.1	37
54	Editorial: New Advances in Neurorehabilitation. Frontiers in Neurology, 2019, 10, 1090.	2.4	10

#	Article	IF	CITATIONS
55	Comparison between physical and cognitive treatment in patients with MCI and Alzheimer's disease. Aging, 2019, 11, 3138-3155.	3.1	33
56	OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity. Toxins, 2019, 11, 359.	3.4	9
57	Improvement of motor performance in children with cerebral palsy treated with exoskeleton robotic training: A retrospective explorative analysis1. Restorative Neurology and Neuroscience, 2019, 37, 239-244.	0.7	10
58	High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde. Internal and Emergency Medicine, 2019, 14, 1271-1278.	2.0	24
59	Mechanisms of Pain. , 2019, , 1-5.		0
60	The Effects of Transcutaneous Spinal Direct Current Stimulation on Neuropathic Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment. Frontiers in Human Neuroscience, 2019, 13, 31.	2.0	24
61	Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction. Journal of Neural Transmission, 2019, 126, 585-595.	2.8	52
62	Non-Aβ-Dependent Factors Associated with Global Cognitive and Physical Function in Alzheimer's Disease: A Pilot Multivariate Analysis. Journal of Clinical Medicine, 2019, 8, 224.	2.4	6
63	Rehabilitation in oldest-old stroke patients: a comparison within over 65 population. European Journal of Physical and Rehabilitation Medicine, 2019, 55, 148-155.	2.2	10
64	Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. European Addiction Research, 2019, 25, 10-19.	2.4	20
65	Exercise Training on Locomotion in Patients with Alzheimer's Disease: A Feasibility Study. Journal of Alzheimer's Disease, 2018, 61, 1599-1609.	2.6	21
66	MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. Movement Disorders, 2018, 33, 499-499.	3.9	9
67	Neuropsychological testing. Practical Neurology, 2018, 18, 227-237.	1.1	35
68	Reply to "Relationship between age and nerve dimensions in Charcot-Marie-Tooth disease. Do we know the reality?― Clinical Neurophysiology, 2018, 129, 1335-1336.	1.5	1
69	Post-traumatic taste disorders: a case series. Journal of Neurology, 2018, 265, 836-844.	3.6	7
70	Nutritional habits, risk, and progression of Parkinson disease. Journal of Neurology, 2018, 265, 12-23.	3.6	45
71	The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study. Clinical Neurophysiology, 2018, 129, 21-32.	1.5	21
72	The Multidisciplinary Approach to Alzheimer's Disease and Dementia. A Narrative Review of Non-Pharmacological Treatment. Frontiers in Neurology, 2018, 9, 1058.	2.4	164

#	Article	IF	CITATIONS
73	A cross-sectional study investigating frequency and features of definitely diagnosed diabetic painful polyneuropathy. Pain, 2018, 159, 2658-2666.	4.2	49
74	Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies. Frontiers in Neurology, 2018, 9, 1018.	2.4	29
75	Impulse Control Disorder in Parkinson's Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates. Frontiers in Neurology, 2018, 9, 654.	2.4	47
76	HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β2-Microglobulin a Missing Piece of the Pathogenetic Puzzle?. Frontiers in Neurology, 2018, 9, 791.	2.4	9
77	Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs. Clinical Neurophysiology, 2018, 129, 2259-2267.	1.5	18
78	Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease. Frontiers in Physiology, 2018, 9, 169.	2.8	38
79	What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications From the Italian Consensus Conference on Pain in Neurorehabilitation. Frontiers in Neurology, 2018, 9, 310.	2.4	40
80	Risky decision-making and affective features of impulse control disorders in Parkinson's disease. Journal of Neural Transmission, 2018, 125, 131-143.	2.8	11
81	Does myofascial and trigger point treatment reduce pain and analgesic intake in patients undergoing onabotulinumtoxinA injection due to chronic intractable migraine?. European Journal of Physical and Rehabilitation Medicine, 2018, 54, 1-12.	2.2	24
82	The role of clinical hypnosis and self-hypnosis to relief pain and anxiety in severe chronic diseases in palliative care: a 2-year long-term follow-up of treatment in a nonrandomized clinical trial. Annals of Palliative Medicine, 2018, 7, 17-31.	1.2	43
83	Efficacy of lidocaine 5% medicated plaster (VERSATIS®) in patients with localized neuropathic pain poorly responsive to pharmacological therapy. Minerva Medica, 2018, 109, 344-351.	0.9	8
84	Working memory in healthy aging and in Parkinson's disease: evidence of interference effects. Aging, Neuropsychology, and Cognition, 2017, 24, 281-298.	1.3	8
85	Aging and risky decision-making: New ERP evidence from the Iowa Gambling Task. Neuroscience Letters, 2017, 640, 93-98.	2.1	28
86	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	2.2	44
87	Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. Journal of Psychopharmacology, 2017, 31, 1369-1373.	4.0	23
88	Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients. American Journal on Addictions, 2017, 26, 610-614.	1.4	13
89	Prevalence of Neuropathic Pain in Patients with Traumatic Brachial Plexus Injury: A Multicenter Prospective Hospital-Based Study. Pain Medicine, 2017, 18, 2428-2432.	1.9	37
90	Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. Journal of Headache and Pain, 2017, 18, 38.	6.0	37

#	Article	IF	CITATIONS
91	Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study. Neurological Sciences, 2017, 38, 137-142.	1.9	53
92	The burden of chronic pain and the role of neurorehabilitation: consensus matters where evidence is lacking. Journal of Pain Research, 2017, Volume 10, 101-103.	2.0	3
93	Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study. PLoS ONE, 2017, 12, e0188994.	2.5	19
94	Determinants of Quality of Life in High-Dose Benzodiazepine Misusers. International Journal of Environmental Research and Public Health, 2017, 14, 38.	2.6	29
95	Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?. Neurological Sciences, 2017, 38, 1461-1468.	1.9	4
96	Vascular Function And Progression Of Alzheimer's Disease. Medicine and Science in Sports and Exercise, 2017, 49, 699.	0.4	0
97	The Italian Consensus Conference on Pain in Neurorehabilitation: rationale and methodology. Journal of Pain Research, 2016, 9, 311.	2.0	14
98	Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson's Disease, 2016, 2016, 1-18.	1.1	161
99	Psychological Treatments and Psychotherapies in the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Frontiers in Psychology, 2016, 7, 115.	2.1	66
100	Psychological Considerations in the Assessment and Treatment of Pain in Neurorehabilitation and Psychological Factors Predictive of Therapeutic Response: Evidence and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. Frontiers in Psychology, 2016, 7, 468.	2.1	43
101	Electrodiagnosis of Lesions of Median and Ulnar Nerve Hand Sensory Branches. Journal of Clinical Neurophysiology, 2016, 33, 454-457.	1.7	3
102	Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management. Movement Disorders, 2016, 31, 1785-1795.	3.9	62
103	The Diagnostic Value of Nerve Ultrasound in an Atypical Palmar Cutaneous Nerve Lesion. American Journal of Physical Medicine and Rehabilitation, 2016, 95, e103-e107.	1.4	4
104	Sunderland's median nerve fascicular anatomy revisited by ultrasound. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 338-339.	1.9	2
105	Combined effects of robot‑assisted gait training and botulinum toxin type A on spastic equinus foot in patients with chronic stroke: a pilot, single blind, randomized controlled trial. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 759-766.	2.2	17
106	Time for a Consensus Conference on pain in neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 714-716.	2.2	1
107	Diagnosing and assessing pain in neurorehabilitation: from translational research to the clinical setting. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 717-729.	2.2	4
108	Assessing and treating pain associated with stroke, multiple sclerosis, cerebral palsy, spinal cord injury and spasticity. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 827-840.	2.2	25

#	Article	IF	CITATIONS
109	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	2.2	14
110	Pharmacological and non-pharmacological strategies in the integrated treatment of pain in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 741-752.	2.2	16
111	The role of gender, psycho-social factors and anthropological-cultural dimensions on pain in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 730-740.	2.2	9
112	Headache, low back pain, other nociceptive and mixed pain conditions in neurorehabilitation. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 867-880.	2.2	10
113	Damage to the Median and Ulnar Nerves After a Snake Bite. Canadian Journal of Neurological Sciences, 2015, 42, 448-449.	0.5	3
114	Isolated musculocutaneous nerve injury in a kickboxer. Muscle and Nerve, 2015, 52, 1137-1139.	2.2	4
115	An electrodiagnostic technique for assessing palmar proper digital nerves of the hand: Normative data and clinical application. Muscle and Nerve, 2015, 52, 972-980.	2.2	5
116	Co-Occurrence of the C9ORF72 Expansion and a Novel GRN Mutation in a Family with Alternative Expression of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Journal of Alzheimer's Disease, 2015, 44, 49-56.	2.6	11
117	The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy. Journal of Diabetes Research, 2015, 2015, 1-7.	2.3	47
118	Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests. Parkinson's Disease, 2015, 2015, 1-10.	1.1	19
119	Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 729-734.	1.9	70
120	Unexpected Inching Explained by an Ulnar Nerve Anatomic Variant Documented by Sonography. Journal of Ultrasound in Medicine, 2015, 34, 1336-1337.	1.7	0
121	Decision and dopaminergic system: an ERPs study of Iowa gambling task in Parkinsonââ,¬â,,¢s disease. Frontiers in Psychology, 2014, 5, 684.	2.1	36
122	Cognition and emotional decision-making in chronic low back pain: an ERPs study during lowa gambling task. Frontiers in Psychology, 2014, 5, 1350.	2.1	51
123	Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial. Frontiers in Human Neuroscience, 2014, 8, 318.	2.0	62
124	Effect of 5% Lidocaine Medicated Plaster on Pain Intensity and Paroxysms in Classical Trigeminal Neuralgia. Annals of Pharmacotherapy, 2014, 48, 1521-1524.	1.9	10
125	Association between Severe Upper Limb Spasticity and Brain Lesion Location in Stroke Patients. BioMed Research International, 2014, 2014, 1-6.	1.9	42
126	Diagnostic and Therapeutic Pitfalls in Considering Chronic Pain as a Disease. Pain Medicine, 2014, 15, 1640-1642.	1.9	2

#	Article	IF	CITATIONS
127	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	1.9	22
128	Painful Legs and Moving Toes Syndrome: Putative Underlying Pathophysiology as a Hint for Combined Pharmacological Treatment?. Movement Disorders Clinical Practice, 2014, 1, 377-378.	1.5	2
129	Relationship Between Ultrasonographic, Electromyographic, and Clinical Parameters in Adult Stroke Patients With Spastic Equinus: An Observational Study. Archives of Physical Medicine and Rehabilitation, 2014, 95, 1564-1570.	0.9	39
130	Longâ€Term Response of Neuropathic Pain to Intravenous Immunoglobulin in Relapsing Diabetic Lumbosacral Radiculoplexus Neuropathy. A Case Report. Pain Practice, 2014, 14, E85-90.	1.9	10
131	Robot-assisted arm training in patients with Parkinson's disease: a pilot study. Journal of NeuroEngineering and Rehabilitation, 2014, 11, 28.	4.6	37
132	Periodic thigh pain from radicular endometriosis. Practical Neurology, 2014, 14, 351-353.	1.1	2
133	Letter to the Editor. Pain, 2014, 155, 201-202.	4.2	0
134	Anti-N-Methyl- <smlcap>D</smlcap> -Aspartate Receptor Encephalitis Causing a Prolonged Depressive Disorder Evolving to Inflammatory Brain Disease. Case Reports in Neurology, 2014, 6, 38-43.	0.7	10
135	Neuropathic pain: diagnosis and treatment. Practical Neurology, 2013, 13, 292-307.	1.1	76
136	No evidence of a neuropathic origin in hemiplegic shoulder pain. Pain, 2013, 154, 958-959.	4.2	2
137	Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Spastic Equinus in Adults With Stroke. American Journal of Physical Medicine and Rehabilitation, 2012, 91, 957-964.	1.4	67
138	Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: Manual needle placement and electrical stimulation guidance compared using ultrasonography. Journal of Rehabilitation Medicine, 2012, 44, 450-452.	1.1	48
139	Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurology, The, 2012, 11, 493-502.	10.2	185
140	Unilateral fixed mydriasis: an uncommon presentation of temporal lobe epilepsy. Journal of Neurology, 2012, 259, 355-357.	3.6	7
141	Median Nerve Small- and Large-Fiber Damage in Carpal Tunnel Syndrome: A Quantitative Sensory Testing Study. Journal of Pain, 2011, 12, 205-212.	1.4	37
142	Immediate versus delayed electrical stimulation boosts botulinum toxin effect: A pilot study. Movement Disorders, 2011, 26, 1785-1786.	3.9	17
143	Guillain-Barré syndrome after short-course efalizumab treatment. Journal of Neurology, 2010, 257, 1404-1405.	3.6	9
144	Central sensitization in carpal tunnel syndrome with extraterritorial spread of sensory symptoms. Pain, 2010, 148, 227-236.	4.2	94

9

#	Article	IF	CITATIONS
145	Central sensitization and sensory symptoms spread in carpal tunnel syndrome: A response to Ginanneschi and Rossi's letter on the relationship between central plastic changes and sensory symptoms in peripheral entrapment neuropathies. Pain, 2010, 150, 370-371.	4.2	0
146	Muscular pain in Parkinson's disease and nociceptive processing assessed with CO ₂ laserâ€evoked potentials. Movement Disorders, 2010, 25, 213-220.	3.9	44
147	Recurrent transitory ischaemic attacks with skin lesions, arthralgia and myalgia should prompt suspicion of atrial myxoma. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 302-303.	1.9	2
148	Intravenous Immunoglobulin for the Treatment of Diabetic Lumbosacral Radiculoplexus Neuropathy. Pain Medicine, 2009, 10, 1476-1480.	1.9	37
149	Ulnar nerve impairment at the wrist does not contribute to extramedian sensory symptoms in carpal tunnel syndrome. Clinical Neurophysiology, 2009, 120, 1687-1692.	1.5	13
150	Hyperalgesia and laser evoked potentials alterations in hemiparkinson: Evidence for an abnormal nociceptive processing. Journal of the Neurological Sciences, 2009, 276, 153-158.	0.6	45
151	The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2008, 270, 18-22.	0.6	36
152	Cingulate Gyrus Tumor Presenting as Panic Attacks. American Journal of Psychiatry, 2008, 165, 651-652.	7.2	11
153	Belly dancer's myoclonus and chronic abdominal pain: Pain-related dysinhibition of a spinal cord central pattern generator?. Parkinsonism and Related Disorders, 2007, 13, 317-320.	2.2	12
154	Proximal pain in patients with carpal tunnel syndrome: a clinical-neurophysiological study. Journal of the Peripheral Nervous System, 2007, 12, 91-97.	3.1	42
155	Extra-median spread of sensory symptoms in carpal tunnel syndrome suggests the presence of pain-related mechanisms. Pain, 2006, 122, 264-270.	4.2	86
156	Sensorimotor integration to cutaneous afferents in humans: the effect of the size of the receptive field. Experimental Brain Research, 2005, 167, 362-369.	1.5	41
157	Abnormalities of sensory processing and sensorimotor interactions in secondary dystonia: A neurophysiological study in two patients. Movement Disorders, 2005, 20, 354-360.	3.9	7
158	A case of oligosymptomatic botulism. The role of single-fiber EMG in early diagnosis. Journal of the Peripheral Nervous System, 2004, 9, 130-131.	3.1	3
159	Motor Responses to Afferent Stimulation in Juvenile Myoclonic Epilepsy. Epilepsia, 2004, 45, 77-80.	5.1	35
160	Stimulus-response properties of motor system in patients with cerebellar ataxia. Clinical Neurophysiology, 2004, 115, 348-355.	1.5	19
161	Enhanced intracortical inhibition in cerebellar patients. Journal of the Neurological Sciences, 2004, 217, 205-210.	0.6	36
162	Modulation of motor cortex excitability after upper limb immobilization. Clinical Neurophysiology, 2004, 115, 1264-1275.	1.5	102

#	Article	IF	CITATIONS
163	Abnormal sensorimotor integration is related to disease severity in Parkinson's disease: A TMS study. Movement Disorders, 2003, 18, 1316-1324.	3.9	26
164	Abnormal cutaneomotor integration in patients with cerebellar syndromes: a transcranial magnetic stimulation study. Clinical Neurophysiology, 2003, 114, 643-651.	1.5	11
165	Abnormal somatotopic arrangement of sensorimotor interactions in dystonic patients. Brain, 2002, 125, 2719-2730.	7.6	87
166	Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2002, 113, 1688-1697.	1.5	133
167	Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis. Journal of Neurology, 2002, 249, 1723-1728.	3.6	87
168	Transient inhibition of the human motor cortex by capsaicin-induced pain. A study with transcranial magnetic stimulation. Neuroscience Letters, 2001, 314, 97-101.	2.1	132
169	Cutaneomotor integration in human hand motor areas: somatotopic effect and interaction of afferents. Experimental Brain Research, 2001, 141, 232-241.	1.5	83
170	Pharmacological treatment for familial amyloid neuropathy. The Cochrane Library, 0, , .	2.8	1